155 related articles for article (PubMed ID: 3305390)
21. [Cutaneous lymphomas : Clinical presentation - diagnosis - treatment].
Wobser M; Goebeler M
Hautarzt; 2019 Oct; 70(10):815-830. PubMed ID: 31511903
[TBL] [Abstract][Full Text] [Related]
22. Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides.
Simoni R; Cavalieri R; Coppola G; Ricciotti L; De Pità O; Criscuolo D; Covelli A; Papa G; Mandelli F
J Biol Regul Homeost Agents; 1987; 1(2):93-9. PubMed ID: 3504088
[TBL] [Abstract][Full Text] [Related]
23. Mycosis fungoides and the Sézary syndrome.
Kim YH; Hoppe RT
Semin Oncol; 1999 Jun; 26(3):276-89. PubMed ID: 10375085
[TBL] [Abstract][Full Text] [Related]
24. Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma.
Kuzel TM; Gilyon K; Springer E; Variakojis D; Kaul K; Bunn PA; Evans L; Roenigk HH; Rosen ST
J Natl Cancer Inst; 1990 Feb; 82(3):203-7. PubMed ID: 2296050
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
Foss FM; Ihde DC; Breneman DL; Phelps RM; Fischmann AB; Schechter GP; Linnoila I; Breneman JC; Cotelingam JD; Ghosh BC
J Clin Oncol; 1992 Dec; 10(12):1907-13. PubMed ID: 1453206
[TBL] [Abstract][Full Text] [Related]
26. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma.
Roenigk HH; Kuzel TM; Skoutelis AP; Springer E; Yu G; Caro W; Gilyon K; Variakojis D; Kaul K; Bunn PA
J Invest Dermatol; 1990 Dec; 95(6 Suppl):198S-205S. PubMed ID: 2258636
[TBL] [Abstract][Full Text] [Related]
27. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
[TBL] [Abstract][Full Text] [Related]
28. Therapy of cutaneous lymphoma--current practice and future developments.
Dummer R; Kempf W; Hess Schmid M; Häffner A; Burg G
Onkologie; 2003 Aug; 26(4):366-72. PubMed ID: 12972705
[TBL] [Abstract][Full Text] [Related]
29. Treatment of cutaneous lymphomas: today and tomorrow.
Mestel DS; Beyer M; Steinhoff M; Sterry W
Actas Dermosifiliogr; 2009 Nov; 100 Suppl 1():18-32. PubMed ID: 20096194
[TBL] [Abstract][Full Text] [Related]
30. Interferon therapy of non-Hodgkin's lymphoma.
Foon KA; Roth MS; Bunn PA
Cancer; 1987 Feb; 59(3 Suppl):601-4. PubMed ID: 3492259
[TBL] [Abstract][Full Text] [Related]
31. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA.
Mostow EN; Neckel SL; Oberhelman L; Anderson TF; Cooper KD
Arch Dermatol; 1993 Jun; 129(6):747-52. PubMed ID: 8507078
[TBL] [Abstract][Full Text] [Related]
32. Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome.
Photiou L; van der Weyden C; McCormack C; Miles Prince H
Curr Oncol Rep; 2018 Mar; 20(4):32. PubMed ID: 29572582
[TBL] [Abstract][Full Text] [Related]
33. Further experience with recombinant interferon alfa-2a with vinblastine in metastatic renal cell carcinoma: a progress report.
Fosså SD; De Garis ST
Int J Cancer Suppl; 1987; 1():36-40. PubMed ID: 3476476
[TBL] [Abstract][Full Text] [Related]
34. Systemic treatment for cutaneous lymphomas.
Mielke V; Staib G; Sterry W
Recent Results Cancer Res; 1995; 139():403-8. PubMed ID: 7597307
[TBL] [Abstract][Full Text] [Related]
35. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.
Trautinger F; Eder J; Assaf C; Bagot M; Cozzio A; Dummer R; Gniadecki R; Klemke CD; Ortiz-Romero PL; Papadavid E; Pimpinelli N; Quaglino P; Ranki A; Scarisbrick J; Stadler R; Väkevä L; Vermeer MH; Whittaker S; Willemze R; Knobler R
Eur J Cancer; 2017 May; 77():57-74. PubMed ID: 28365528
[TBL] [Abstract][Full Text] [Related]
36. Combined modality therapy with electron-beam irradiation and systemic chemotherapy for cutaneous T-cell lymphomas.
Bunn PA; Fischmann AB; Schechter GP; Kumar PP; Ihde DC; Cohen MH; Fossieck BE; Gazdar AF; Matthews MJ; Eddy JL; Minna JD
Cancer Treat Rep; 1979 Apr; 63(4):713-7. PubMed ID: 109208
[No Abstract] [Full Text] [Related]
37. [Alpha interferon in therapy of non-Hodgkin's lymphoma].
Freund M; Hanauske AR
Onkologie; 1990 Dec; 13(6):424-8. PubMed ID: 2092278
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous T cell lymphomas: mycosis fungoides, Sézary syndrome and lymphomatoid papulosis--Part I.
Safai B
Clin Bull; 1977; 7(3):91-7. PubMed ID: 308870
[No Abstract] [Full Text] [Related]
39. Integrating novel systemic therapies for the treatment of mycosis fungoides and Sézary syndrome.
Prince HM; Querfeld C
Best Pract Res Clin Haematol; 2018 Sep; 31(3):322-335. PubMed ID: 30213403
[TBL] [Abstract][Full Text] [Related]
40. Primary cutaneous pleomorphic small T-cell lymphoma. A review of 11 cases. The French Study Group on Cutaneous Lymphomas.
Friedmann D; Wechsler J; Delfau MH; Estève E; Farcet JP; de Muret A; Parneix-Spake A; Vaillant L; Revuz J; Bagot M
Arch Dermatol; 1995 Sep; 131(9):1009-15. PubMed ID: 7661602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
